Rigshospitalet is the largest hospital in Denmark and the most highly specialised hospital in the country. The hospital's main building is a 16-storey functionalist highrise, one of the tallest structures in the central parts of the city.

There are 1,118 beds in Department of Oncology, Rigshospitalet.

During the past decade, Department of Oncology, Rigshospitalet conducted 15 clinical trials. In the 10-year time frame, 15 clinical trials started and 2 clinical trials were completed, i.e. on average, 13.3% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 2 clinical trials were completed. i.e. 66.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Department of Oncology, Rigshospitalet" #1 sponsor was "Rigshospitalet, Denmark" with 10 trials, followed by "University of Copenhagen" with 4 trials sponsored, "Vejle Hospital" with 3 trials sponsored, "Danish Breast Cancer Cooperative Group" with 2 trials sponsored and "Dr Anders Ullén" with 2 trials sponsored. Other sponsors include 5 different institutions and companies that sponsored additional 15 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Department of Oncology, Rigshospitalet" #1 collaborator was "Aalborg University Hospital" with 2 trials as a collaborator, "Hoffmann-La Roche" with 2 trials as a collaborator, "Odense University Hospital" with 2 trials as a collaborator, "Sanofi" with 2 trials as a collaborator and "ADIR, a Servier Group company" with 1 trials as a collaborator. Other collaborators include 15 different institutions and companies that were collaborators in the rest 25 trials.

According to Clinical.Site data, the most researched conditions in "Department of Oncology, Rigshospitalet" are "Bladder Cancer" (3 trials), "Urothelial Carcinoma" (3 trials), "Metastatic Colorectal Cancer" (2 trials), "Mucositis" (2 trials) and "Non Small Cell Lung Cancer" (2 trials). Many other conditions were trialed in "Department of Oncology, Rigshospitalet" in a lesser frequency.

Most popular intervention types in "Department of Oncology, Rigshospitalet" are "Drug" (19 trials), "Dietary Supplement" (4 trials), "Biological" (2 trials), "Device" (2 trials) and "Other" (2 trials). Other intervention types were less common.

The name of intervention was led by "Gemcitabine" (4 trials), "Cisplatin" (3 trials), "Paclitaxel" (2 trials), "Vinflunine" (2 trials) and "ALECSAT" (1 trials). Other intervention names were less common.

The vast majority of trials in "Department of Oncology, Rigshospitalet" are 25 trials for "All" genders, 3 trials for "Female" genders and 3 trials for "Male" genders.

Currently, there are NaN active trials in "Department of Oncology, Rigshospitalet". undefined are not yet recruiting, 2 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 14 completed trials in Department of Oncology, Rigshospitalet, undefined suspended trials, and 7 terminated clinical trials to date.

Out of the total trials that were conducted in Department of Oncology, Rigshospitalet, 3 "Phase 1" clinical trials were conducted, 15 "Phase 2" clinical trials and 6 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 3 trials that are defined as “Not Applicable".